MA54460A - Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine - Google Patents
Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridineInfo
- Publication number
- MA54460A MA54460A MA054460A MA54460A MA54460A MA 54460 A MA54460 A MA 54460A MA 054460 A MA054460 A MA 054460A MA 54460 A MA54460 A MA 54460A MA 54460 A MA54460 A MA 54460A
- Authority
- MA
- Morocco
- Prior art keywords
- water
- pharmaceutical formulations
- based pharmaceutical
- dihydropyridine compounds
- dihydropyridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779620P | 2018-12-14 | 2018-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54460A true MA54460A (fr) | 2021-10-20 |
Family
ID=69174604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054460A MA54460A (fr) | 2018-12-14 | 2019-12-16 | Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12303499B2 (https=) |
| EP (1) | EP3893844A1 (https=) |
| JP (1) | JP7177937B2 (https=) |
| KR (1) | KR102912861B1 (https=) |
| CN (1) | CN113226286B (https=) |
| AU (1) | AU2019395288B2 (https=) |
| BR (1) | BR112021010953A2 (https=) |
| CA (1) | CA3122705A1 (https=) |
| MA (1) | MA54460A (https=) |
| MX (1) | MX2021006317A (https=) |
| WO (1) | WO2020124090A1 (https=) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
| HU223945B1 (hu) | 1994-09-27 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények |
| US5935551A (en) | 1995-11-15 | 1999-08-10 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite P1 |
| DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
| KR100375155B1 (ko) | 1996-05-15 | 2003-08-19 | 화이자 인코포레이티드 | 신규한2,3-이치환된-4(3에이치)-퀴나졸리논 |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| SK113299A3 (en) | 1997-02-28 | 2001-05-10 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
| JP2002519373A (ja) | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
| DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
| IL152848A0 (en) | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| WO2007072869A1 (ja) * | 2005-12-21 | 2007-06-28 | Eisai R & D Management Co., Ltd. | 1,2-ジヒドロピリジン化合物の非晶質体 |
| US20100099714A1 (en) * | 2007-03-05 | 2010-04-22 | Eisai R&D Management Co., Ltd. | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases |
| JP2015227288A (ja) | 2012-08-31 | 2015-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | けいれん重積発作の治療用医薬組成物 |
| CN104644592A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种吡仑帕奈药物组合物及其制备方法 |
| CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
| EP4059522A1 (en) * | 2015-02-06 | 2022-09-21 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| CN106389367B (zh) | 2016-11-16 | 2020-12-18 | 杭州朱养心药业有限公司 | 吡仑帕奈包衣片剂药物组合物 |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
-
2019
- 2019-12-16 WO PCT/US2019/066622 patent/WO2020124090A1/en not_active Ceased
- 2019-12-16 JP JP2021530970A patent/JP7177937B2/ja active Active
- 2019-12-16 EP EP19839214.4A patent/EP3893844A1/en active Pending
- 2019-12-16 CA CA3122705A patent/CA3122705A1/en active Pending
- 2019-12-16 CN CN201980081856.7A patent/CN113226286B/zh active Active
- 2019-12-16 BR BR112021010953-6A patent/BR112021010953A2/pt unknown
- 2019-12-16 MX MX2021006317A patent/MX2021006317A/es unknown
- 2019-12-16 AU AU2019395288A patent/AU2019395288B2/en active Active
- 2019-12-16 US US17/312,077 patent/US12303499B2/en active Active
- 2019-12-16 KR KR1020217017514A patent/KR102912861B1/ko active Active
- 2019-12-16 MA MA054460A patent/MA54460A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019395288B2 (en) | 2025-04-03 |
| CA3122705A1 (en) | 2020-06-18 |
| JP2022510947A (ja) | 2022-01-28 |
| BR112021010953A2 (pt) | 2021-08-24 |
| US20220023275A1 (en) | 2022-01-27 |
| CN113226286A (zh) | 2021-08-06 |
| KR102912861B1 (ko) | 2026-01-15 |
| KR20210107644A (ko) | 2021-09-01 |
| AU2019395288A1 (en) | 2021-09-23 |
| US12303499B2 (en) | 2025-05-20 |
| MX2021006317A (es) | 2021-08-11 |
| CN113226286B (zh) | 2024-08-20 |
| EP3893844A1 (en) | 2021-10-20 |
| WO2020124090A1 (en) | 2020-06-18 |
| JP7177937B2 (ja) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52421A (fr) | Composés pharmaceutiques | |
| EP3442973A4 (en) | INNOVATIVE COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREFOR | |
| IL283134A (en) | Alcohol-resistant drug formulations | |
| EP3548000A4 (en) | PHARMACEUTICAL COMPOSITIONS OF ATROPINE | |
| EP3843704A4 (en) | EMULSION FORMULATIONS OF MULTIKINAS INHIBITORS | |
| EP3328843A4 (en) | 1,3,4-OXADIAZOLSULFONAMID DERIVATIVE COMPOUNDS AS A HISTONDEACETYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| EP3256149A4 (en) | FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES | |
| MX2020011478A (es) | Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos. | |
| EP3405183A4 (en) | ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION | |
| MA49393A (fr) | Poly(phosphoesters) destinés à l'administration d'acides nucléiques | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| MA50356A (fr) | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 | |
| MA50250A (fr) | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 | |
| EP3399979A4 (en) | FORMULATIONS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPER-IDIN-3-YL) -1-OX-O-SO-ISOLIN-5-YL) METHYL) -2,2-DIFLUOROETAMIDE | |
| EP3917926A4 (en) | IMIDAZOCHINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF | |
| EP3880671A4 (en) | NOVEL COMPOUND AS A PROTEIN KINAS INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | |
| EP3897593A4 (en) | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| EP4015001A4 (en) | Oral pharmaceutical composition | |
| EP3452441A4 (en) | ALPHA-TRUXILLINIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF | |
| EP3677652A4 (en) | WATER BASED INK COMPOSITION | |
| EP3976025A4 (en) | PSMA IMAGING AGENT FORMULATIONS | |
| EP3582759A4 (en) | BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF PRE-ORDIOXETINE HYDROBROMIDE |